FDA Approves Mavacamten for Hypertrophic Cardiomyopathy.

DRUG approval; CARDIAC hypertrophy; AMINES; UNITED States. Food & Drug Administration; DRUG labeling; COST effectiveness; ADULTS

The article reports that Camzyos or mavacamten from Bristol Myers Squibb has been approved by the U.S. Food and Drug Administration for the treatment of obstructive hypertrophic cardiomayopathy (HCM) in adults. An overview of the phase 3 EXPLORER-HCM clinical trial on the safety and effectiveness of Camzyos for improving symptoms, functional status, quality of life and relieving left ventricular obstruction fraction is provided.